Barbee LA, et al. - In view of the observed recommendation of ceftriaxone 250 mg plus azithromycin (AZM) 1 g for gonorrhea treatment, researchers assessed if resistance to AZM could affect gonorrhea control efforts. They recognized gonorrhea with reduced susceptibility to AZM in 5% of men who have sex with men (MSM) with gonorrhea in Seattle. Changing treatment guidelines were recommended by the World Health Organization when >5% of isolates are resistant to a recommended drug. The emergence of resistant AZM gonorrhea should prompt reconsideration of current treatment recommendations, and highlighted the necessity for new therapies for gonorrhea.